Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00265980 · ClinicalTrials.gov registry record · NA
Leptin in Human Energy and Neuroendocrine Homeostasis
A NA study, sponsored by Columbia University.
- Terminated
- Registry status
- NA
- Development phase
- 22
- Enrollment target
NCT00265980 is a NA study that was terminated before completion, run by Columbia University. The registered enrollment target is 22 participants.
The verdict
NCT00265980, a NA study, was terminated before completion, sponsored by Columbia University.
- TERMINATED
- Registry status
- NA
- Development phase
- 22 participants
- Enrollment target
Study Summary
Previous work in our laboratory, and many others, has shown that body weight is regulated. When anyone, fat or thin, tries to maintain a reduced body weight, many systems affecting energy balance (skeletal muscle, neuroendocrine, and autonomic systems) conspire to slow metabolic rate thus favoring the regain of lost weight. Individuals with leptin deficiency are remarkably similar to weight-reduced individuals. Their metabolism, thyroid hormones, and sympathetic nervous system activity are all low despite their obesity. While administration of leptin to leptin-deficient humans results in substantial weight loss and increases in energy expenditure. However, leptin administration to leptin-sufficient humans at usual body weight has little or no effect on weight unless given in doses 10-20 times what would be considered to be in the normal physiological range. This study examines the hypothesis that leptin is "read" by various systems regulating energy balance as an indicator of how much energy we have stored and that the body perceives the weight-reduced state as a condition of relative leptin insufficiency. Within this model, restoration of leptin to levels present prior to weight loss should relieve much of the metabolic opposition to keeping weight off. Preliminary studies support this hypothesis.
Interventions
- DRUG Leptin
- DRUG Subcutaneous Placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2002-07 |
| Est. Completion | 2013-07 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00265980
The ClinicalTrials.gov registry entry for NCT00265980 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Columbia University, which has 958 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Leptin is the first listed.
NCT00265980 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00265980 about?
NCT00265980 is a clinical study titled "Leptin in Human Energy and Neuroendocrine Homeostasis". Previous work in our laboratory, and many others, has shown that body weight is regulated. When anyone, fat or thin, tries to maintain a reduced body weight, many systems affecting energy balance (skeletal muscle, neuroendocrine, and autonomic systems) conspire to slow metabolic rate thus favoring t...
What is the current status of trial NCT00265980?
This trial is currently terminated. It is a NA study. The enrollment target is 22 participants. The study started on 2002-07. Estimated completion is 2013-07.
What interventions are being tested in trial NCT00265980?
The interventions under investigation include: Leptin (DRUG), Subcutaneous Placebo (DRUG).
Who is sponsoring clinical trial NCT00265980?
This trial is sponsored by Columbia University, which has 958 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.